top of page

NCI-2024-03914

Updated: Feb 21

Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants with Advanced Solid Tumors


This Phase 1 clinical trial investigates RP-1664 in participants with advanced solid tumors. The study focuses on assessing the safety, pharmacokinetics (how the drug moves in the body), pharmacodynamics (how the drug affects the body), and initial clinical activity of RP-1664. The goal is to understand how well the drug works and its safety profile in treating advanced solid tumors.


For more information about the trial, click the link below:

Clinical Trial Site: Columbia


To see all available clinical trials click here.



 
 
 

Recent Posts

See All
NCI-2025-04391

A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy andSafety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants withResected or Unresec

 
 
 
NCI-2025-05085

A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB1305 in Participants with Advanced/Metastatic Solid Tumors This Phase 2 , multicenter, open-label research study i

 
 
 
NCI-2025-07002

A Phase 1b, Two-Part Study of Tolododekin Alfa (ANK-101) in Combination with an Anti-PD-1/PD-L1 Antibody in Participants with Advanced Non-Small Cell Lung Cancer This Phase 1b, two-part research study

 
 
 

Comments

bottom of page